{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:23:13Z","timestamp":1740162193904,"version":"3.37.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005845","name":"Hyogo Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinre.2024.102497","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T17:20:25Z","timestamp":1731691225000},"page":"102497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles\u2014A pilot study in a single institution"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7567-9263","authenticated-orcid":false,"given":"Kan","family":"Toriguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2024.102497_bib0001","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102497_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular carcinoma","volume":"73 Suppl 1","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2024.102497_bib0003","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/liv.13613","article-title":"More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma","volume":"38","author":"Jun","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0004","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clinre.2024.102497_bib0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic medicine and implications for hepatocellular carcinoma prevention and therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2004.02.021","article-title":"A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient","volume":"127","author":"Tamborini","year":"2004","journal-title":"Gastroenterology"},{"issue":"5531","key":"10.1016\/j.clinre.2024.102497_bib0007","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.clinre.2024.102497_bib0008","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clinre.2024.102497_bib0009","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-04-0085","article-title":"A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clinre.2024.102497_bib0010","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"5848","key":"10.1016\/j.clinre.2024.102497_bib0011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.clinre.2024.102497_bib0012","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0013","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"19","key":"10.1016\/j.clinre.2024.102497_bib0014","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-019-6057-7","article-title":"Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"6","key":"10.1016\/j.clinre.2024.102497_bib0017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2024.102497_bib0018","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.dld.2011.03.009","article-title":"Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection","volume":"43","author":"Bruno","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159530","article-title":"Assessment of preoperative liver function in patients with hepatocellular carcinoma - the Albumin-Indocyanine Green Evaluation (ALICE) grade","volume":"11","author":"Kokudo","year":"2016","journal-title":"PloS one"},{"key":"10.1016\/j.clinre.2024.102497_bib0021","series-title":"R foundation for statistical computing","article-title":"A language and environment for statistical computing","author":"Team","year":"2021"},{"issue":"3","key":"10.1016\/j.clinre.2024.102497_bib0022","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3892\/etm.2011.215","article-title":"Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma","volume":"2","author":"Liu","year":"2011","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.clinre.2024.102497_bib0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jss.2010.05.023","article-title":"Predicting the prognosis of hepatocellular carcinoma using gene expression","volume":"171","author":"Chang","year":"2011","journal-title":"J Surg Res"},{"issue":"8","key":"10.1016\/j.clinre.2024.102497_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002551","article-title":"Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB","volume":"9","author":"Fridland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinre.2024.102497_bib0025","article-title":"The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA","author":"Lee","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clinre.2024.102497_bib0026","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.3892\/ijo.2015.2910","article-title":"ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling","volume":"46","author":"Xie","year":"2015","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102497_bib0027","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cbf.3522","article-title":"Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN\/AKT\/mTOR pathway","volume":"38","author":"Wang","year":"2020","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0028","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3892\/ijo.2015.3244","article-title":"Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression","volume":"48","author":"Duan","year":"2016","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102497_bib0029","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-18-3531","article-title":"Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma","volume":"26","author":"Tsai","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2024.102497_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.phrs.2015.08.010","article-title":"Fyn is an important molecule in cancer pathogenesis and drug resistance","volume":"100","author":"Elias","year":"2015","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0031","first-page":"4554","article-title":"Unique catalytic properties dictate the enhanced function of p59fynT, the hemopoietic cell-specific isoform of the Fyn tyrosine protein kinase, in T cells","volume":"14","author":"Davidson","year":"1994","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0032","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/cdd.2015.66","article-title":"Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity","volume":"23","author":"Zhang","year":"2016","journal-title":"Cell Death Differ"},{"issue":"15","key":"10.1016\/j.clinre.2024.102497_bib0033","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/onc.2014.138","article-title":"Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy","volume":"34","author":"Elias","year":"2015","journal-title":"Oncogene"},{"issue":"27","key":"10.1016\/j.clinre.2024.102497_bib0034","doi-asserted-by":"crossref","first-page":"23631","DOI":"10.18632\/oncotarget.4604","article-title":"A NOX2\/Egr-1\/Fyn pathway delineates new targets for TKI-resistant malignancies","volume":"6","author":"Irwin","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.clinre.2024.102497_bib0035","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Fenouille","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0036","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.24879","article-title":"Fyn: a novel molecular target in cancer","volume":"116","author":"Saito","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clinre.2024.102497_bib0037","first-page":"646","article-title":"Oncogenic role of LYN in human gastric cancer via the Wnt\/beta-catenin and AKT\/mTOR pathways","volume":"20","author":"Su","year":"2020","journal-title":"Exp Ther Med"},{"issue":"36","key":"10.1016\/j.clinre.2024.102497_bib0038","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2024.102497_bib0039","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:48:28Z","timestamp":1733363308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2210740124002183"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102497","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles\u2014A pilot study in a single institution","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102497"}}